| top | |
| BRAINLIFE NEWSLETTER | |
Volume 3, Number 21 - 23 June
2004 |
|
|
|
|
|
Contents |
|
|
|
|
| Etiology & Pathogenesis | |
| Overall Management | |
| Prognosis & Outcome | |
| Psychosocial Aspects | |
| Treatment | |
|
|
|
|
|
|
|
|
|
|
D. S. Keith, D. T. Blumenthal,
L. A. Cannon-Albright
The familiality of primary brain tumors as studied in the Utah Population Database (UPDB) 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1526 |
|
|
|
|
|
|
|
|
|
|
|
G. M. Videtic, D. J. Adelstein,
T. Mekhail, T. W. Rice, G. H. J. Stevens, S.-Y. Lee, J. H. Suh
Validation of the RTOG recursive partitioning analysis (RPA) classification for small cell lung cancer-only brain metastases: A single institution experience 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1557 |
|
|
|
|
|
|
|
|
|
|
|
M. Frenay, A. Ramaioli, D.
Fontaine, V. Bourg, F. Vandenbos, C. Lebrun
Prognostic factors of oligodendrogliomas 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1560 |
|
|
B. E. Lally, J. M. Colasanto,
J. P. S. Knisely
The prognostic effect of hemoglobin levels on survival for patients with high-grade gliomas 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1565 |
|
|
|
|
|
|
|
|
|
|
|
P. D. Brown, K. V. Ballman, T. A.
Rummans, M. J. Maurer, J. A. Sloan, B. F. Boeve, R. M. Arusell, M. M. Clark, J.
C. Buckner
Prospective NCCTG quality of life (QOL) study in adult newly diagnosed high-grade gliomas (HGG) 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1524 |
|
|
|
|
|
|
|
|
|
|
|
W. O. Arafat, D. Rein, D.
Buchsbaum, D. Curiel, Z. Zhu
Survivin as a novel radiation/CIS platinum/tumor specific promoter for conditional oncolytic viral therapy 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1535 |
|
|
M. A. Badruddoja, D. A. Reardon, G.
Akabani, A. H. Friedman, H. S. Friedman, J. N. Rich, J. A. Quinn, K. Penne, J.
J. Vredenburgh, D. D. Bigner
Phase II trial of iodine 131-labeled murine anti-tenascin monoclonal anti-body 81C6 (M81C6) via surgically created resection cavity in the treatment of patients with recurrent malignant brain tumors 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1569 |
|
|
T. Batchelor, S. Grossman, K.
Carson, J. Fisher
Updated results from NABTT CNS consortium studies in primary CNS lymphoma 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1519 |
|
|
U. Bogdahn, P. Hau, A.
Brawanski, J. Schlaier, M. Mehdorn, G. Wurm, J. Pichler, M. Kunst, G.
Stauder, K.-H. Schlingensiepen
Specific therapy for high-grade glioma by convection-enhanced delivery of the TGF-β2 specific antisense oligonucleotide AP 12009 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1514 |
|
|
A. A. Brandes, A. Tosoni, M.
Reni, F. Valduga, U. Basso, S. Lonardi, L. M. Pasetto, V. Blatt, S.
Monfardini, M. Ermani
Second line BCNU plus CPT-11 chemotherapy in recurrent glioblastoma (GBM): Phase II study of GICNO (Italian Neuro-Oncology Group) 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1516 |
|
|
S. Brem, S. A. Grossman, K. A.
Carson, P. New, S. Phuphanich, J. B. Alavi, T. Mikkelsen, R. Priet
Phase II trial of copper depletion as angiosuppressive treatment in newly diagnosed Glioblastoma Multiforme: Final report 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1530 |
|
|
M. Caraglia, R. Addeo, R.
Costanzo, L. Montella, V. Faiola, E. Capasso, S. Del Prete
Pegylated liposomal doxorubicin plus temozolamide in the salvage treatment of brain metastases: The update 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1576 |
|
|
S.
E. Combs, S. Gutwein, D. Schulz-Ertner, M. Van Kampen, C. Thilmann, M.
M. Wannenmacher, J. Debus
Temozolomide combined with radiation as first-line treatment in primary glioblastoma multiforme: Phase I/II-study 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1531 |
|
|
A. Desjardins, J. A. Quinn, D. A.
Reardon, J. N. Rich, J. J. Vredenburgh, C. Efird, H. S. Friedman
Phase II study of thalidomide and daily cyclophosphamide for adults with malignant glioma 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1554 |
|
| A. I. Freeman,
J. M. Gomori, E. Linetsky, Z. Zakay-Rones, A. Panet, E. Libson, C. S.
Irving, E. Galun, T. Siegal
Phase I/II trial of intravenous OV001 oncolytic virus in resistant glioblastoma multiforme (GBM) 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1515 |
|
|
M. W. Kieran, R. Packer, J. Boyett, M. Sugrue, L. Kun, Pediatric Brain Tumor
Consortium (PBTC)
Phase I trial of the oral farnesyl protein transferase inhibitor lonafarnib (SCH66336): A Pediatric Brain Tumor Consortium (PBTC) study 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1517 |
|
|
R. R. Maņon, A. Oneill, M. Mehta,
J. Knisely, M. Werner-Wasik, H. Lazarus, H. Wagner, M. Gilbert
Phase II trial of radiosurgery (RS) for 1 to 3 newly diagnosed brain metastases from renal cell, melanoma, and sarcoma: An Eastern Cooperative Oncology Group Study (E6397) 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1507 |
|
|
P. L. Moots, A. O'Neill, G. R.
Barger, M. P. Mehta, M. R. Gilbert
Toxicities associated with chemotherapy followed by craniospinal radiation for adults with poor-risk medulloblastoma/PNET and disseminated ependymoma; a preliminary report of ECOG 4397 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1573 |
|
|
B. Neyns, E. Everaert, E.
Joosens, T. Strauven, F. Branle, J. Menten
Temozolomide for the treatment of recurrent glioma: Results of a compassionate use program in Belgium 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1541 |
|
|
C. Nieder, N. Wiedenmann, S.
Stark, A. L. Grosu
Phase II trial of functional imaging-optimized stereotactic fractionated radiotherapy plus temozolomide for recurrent high-grade glioma 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1552 |
|
|
S. Pannullo, S. Hariharan, J.
Serventi, R. Hayes, C. Balmaceda, J. Burton
Phase I/II trial of a twice-daily regimen of temozolomide and celecoxib for treatment of relapsed/refractory glioblastoma multiforme and anaplastic astrocytoma 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1549 |
|
|
M. Prados, W. Yung, P. Wen, L.
Junck, K. Fink, T. Cloughesy, I. Robins, S. Chang, J. Kuhn Phase I study of ZD1839 plus temozolomide in patients with malignant glioma. A study of the North American Brain Tumor Consortium 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1504 |
|
|
J. M. Simon, G. Noel, K.
Hoang-Xuan, A. F. Carpentier, K. Mokhtari, S. Racadot, F. Baillet, J. J.
Mazeron
Radiotherapy and concomitant weekly carboplatin and daily etoposide for patients with inoperable biopsy proven glioblastoma multiforme 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1544 |
|
|
M. A. Spear, A. Mirmiran, E. McClay
Phase I/II trial of IV topotecan (TOPO) in combination with whole brain radiation therapy (WBXRT) 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1553 |
|
| S.
Tafuto, R. Guarrasi, A. Tortoriello, F. Buzzi, P. Muto, R. Formato, P.
Comella, P. De Rosa, R. V. Iaffaioli, S. Quattrin
Temozolomide (TMZ) and lomustine (CCNU) in high grade glioma (HGG) patients: Phase I study 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1577 |
|
|
J. H. Uhm, K. V. Ballman, C.
Giannini, J. C. Krauss, J. C. Buckner, D. James, B. W. Scheithauer, J. R.
O'Fallon, K. A. Jaeckle
Phase II study of ZD1839 in patients with newly diagnosed grade 4 astrocytoma 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1505 |
|
